NEWS
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Dermata Therapeutics (Nasdaq: DRMA) has announced 50% enrollment in its pivotal Phase 3 STAR-1 clinical trial for DMT310, a novel once-weekly topical treatment for moderate-to-severe acne. The study, which began in December 2023, is the first of two Phase 3 trials aimed at supporting a new drug application (NDA) for DMT310. Topline results are expected in Q1 2025.
The STAR-1 trial is a randomized, double-blind, placebo-controlled study enrolling approximately 550 patients aged 9 and older in the U.S. and Latin America. Primary endpoints include changes in lesion counts and Investigator Global Assessment scores. If approved, DMT310 could become the first once-weekly topical acne treatment, potentially addressing a significant market with about 30 million U.S. acne patients seeking treatment annually.
The STAR-1 trial is a randomized, double-blind, placebo-controlled study enrolling approximately 550 patients aged 9 and older in the U.S. and Latin America. Primary endpoints include changes in lesion counts and Investigator Global Assessment scores. If approved, DMT310 could become the first once-weekly topical acne treatment, potentially addressing a significant market with about 30 million U.S. acne patients seeking treatment annually.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1259Followers
76Following
8844Visitors
Follow